Показано 0 из 0
Дата |
---|
24.04.2024 |
09.01.2024 |
13.12.2023 |
27.09.2023 |
18.07.2023 |
18.05.2023 |
04.10.2022 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
|
|
|
6 385.68
|
6 385.68
|
6 385.68
|
|
|
402 297.84
|
|
|
|
|
6 908.59
|
6 908.59
|
6 908.59
|
|
|
1 381 718.00
|
|
|
|
|
|
|
8 514.08
|
|
|
1 984 812.50
|
|
|
|
|
|
|
8 514.08
|
|
|
5 938 506.00
|
|
|
|
|
8 514.08
|
8 514.08
|
8 514.08
|
|
|
6 811 264.00
|
|
|
|
|
7 368.49
|
7 368.49
|
7 368.49
|
|
|
736 849.00
|
|
|
|
|
7 342.15
|
7 342.15
|
7 342.15
|
|
|
5 873 720.00
|
|
Argenx S.E., a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer.